Search - tctmd.com

Displaying 1 - 20 of 52

Sort: Relevancy | Date

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

News Conference News PCR London Valves 2022

Earlier Interventions and Later Redos? ‘Mature’ TAVI Still Has Growing Pains

November 28, 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

News Conference News AHA 2022

Drug Preconditioning Before CABG, Valve Surgery Shows Promise: START

November 14, 2022

STRESS Shows ‘Borderline Results’ for Methylprednisolone in Infant Cardiac Surgery

News Conference News AHA 2022

STRESS Shows ‘Borderline Results’ for Methylprednisolone in Infant Cardiac Surgery

Yael L. Maxwell

November 11, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

November 08, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

News Conference News AHA 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

November 07, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

News Conference News EACTS 2022

Adjunctive Radial Artery Grafts No Better Than SVGs in Multivessel CABG

Michael O'Riordan

October 12, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

News Conference News TCT 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

Yael L. Maxwell

September 21, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.